BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24828264)

  • 1. Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI.
    Zhang Z; Jiang H; Chen X; Bai J; Cui Y; Ren X; Chen X; Wang J; Zeng W; Lin S
    J Neurooncol; 2014 Aug; 119(1):207-14. PubMed ID: 24828264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
    Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pretreatment glioblastoma: Prognostic value of MRI-based radiomics.
    Choi Y; Ahn KJ; Nam Y; Jang J; Shin NY; Choi HS; Jung SL; Kim BS
    Eur J Radiol; 2019 Nov; 120():108642. PubMed ID: 31546124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
    Naeini KM; Pope WB; Cloughesy TF; Harris RJ; Lai A; Eskin A; Chowdhury R; Phillips HS; Nghiemphu PL; Behbahanian Y; Ellingson BM
    Neuro Oncol; 2013 May; 15(5):626-34. PubMed ID: 23444259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
    Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
    J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
    BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
    Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
    Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants.
    Alimohammadi E; Bagheri SR; Sadeghsalehi A; Rizevandi P; Rezaie Z; Abdi A
    Acta Neurol Belg; 2020 Dec; 120(6):1341-1350. PubMed ID: 31222512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
    Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
    PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
    Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
    Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.